Roland Magnusson/iStock Editorial via Getty Images BenevolentAI ( OTC:BAIVF ) Tuesday said that AstraZeneca ( NASDAQ: AZN ) has added a novel target for systemic lupus erythematosus to its discovery portfolio through its collaboration with the company. This is the second target to be selected this year from the extended collaboration with AstraZeneca ( AZN ), highlighting continued positive progress in the field of target identification, BenevolentAI ( OTC:BAIVF ) added. BenevolentAI’s collaboration with AstraZeneca began in 2019 in idiopathic pulmonary fibrosis and chronic kidney disease , with the collaboration expanded in January 2022 to include heart failure and SLE.
SLE, or lupus, is a chronic autoimmune disease where the immune system mistakenly identifies the body’s own tissues as foreign. Source: Press Release More on AstraZeneca, BenevolentAI S.A.
, etc. AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca breast cancer therapy fails in late-stage trial AstraZeneca gets FDA okay for Imfinzi for endometrial cancer.